Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...

Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology -NSI-189 Showed Durable Functional Recovery in a Rodent Model of Ischemic Stroke- -NSI-189 Promoted Synaptic Remodeling After Stroke- GERMANTOWN, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...

Neuralstem Announces Issuance of U.S. Patent Covering NSI-189 GERMANTOWN, Md., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...

Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD. GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...